Not applicableStudy completedNCT02090543What this trial is testingBAY 59-7939 (Xarelto, SPAF), Non Interventional StudiesWho this might be right forAtrial Fibrillation Bayer 647
Large-scale testing (Phase 3)Study completedNCT02942576What this trial is testingEdoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationWho this might be right forAtrial Fibrillation Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 632
Post-approval studies (Phase 4)Study completedNCT01727453What this trial is testingCompare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.Who this might be right forAcute Gastrointestinal Bleeding Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 40
Large-scale testing (Phase 3)Study completedNCT01674647What this trial is testingExplore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionWho this might be right forAtrial Fibrillation Bayer 1,504
Not applicableUnknownNCT04462614What this trial is testingPossibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKAWho this might be right forChronic HemolysisVKAAnticoagulants / Administration & Dosage+7 more CHU de Reims 49
Not applicableStudy completedNCT03826927What this trial is testingNew Oral Anticoagulants (NOAC) in Stroke PatientsWho this might be right forStrokeAtrial Fibrillation University Hospital, Basel, Switzerland 1,023
Testing effectiveness (Phase 2)Study completedNCT00623779What this trial is testingAtrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)Who this might be right forPersistent or Permanent Non-valvular Atrial Fibrillation AstraZeneca 128
Testing effectiveness (Phase 2)Study completedNCT05205863What this trial is testingDose-Response in PD and Safety of Cofact Under VKA AnticoagulationWho this might be right forHealthy Volunteers Prothya Biosolutions 69
Not applicableStudy completedNCT02657616What this trial is testingStroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKAWho this might be right forAtrial FibrillationStroke Prophylaxis Institut für Pharmakoökonomie und Arzneimittellogistik e.V. 204,464
Not applicableStudy completedNCT02240667What this trial is testingDrug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)Who this might be right forAtrial Fibrillation Boehringer Ingelheim 1,506
Not applicableNot Yet RecruitingNCT07570511What this trial is testingPoint of Care Testing INR in Antiphospholipid SyndromeWho this might be right forAntiphospholipid SyndromeVitamine K Antagonist (VKA) Treatment Central Hospital, Nancy, France 150
Large-scale testing (Phase 3)Study completedNCT00062803What this trial is testingSR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary EmbolismWho this might be right forPulmonary Embolism Sanofi
Not applicableStudy completedNCT03532724What this trial is testingClinical Outcomes From Patient Self-management of Antivitamin K TreatmentWho this might be right forSelf Management of Oral Anticoagulation With VKA Therapy Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 927
Not applicableStudy completedNCT02843958What this trial is testingValidation of a Portable Medical Device for Diagnostic in VitroWho this might be right forHealthy VolunteerPatients Under Vitamin K Antagonist (VKA) University Hospital, Grenoble 40
Not applicableStudy completedNCT03462446What this trial is testingAnalysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists EventsWho this might be right forAtrial Fibrillation Bayer 249
Not applicableNot Yet RecruitingNCT06884384What this trial is testingDOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort StudyWho this might be right forAntiphospholipid Syndrome (APS)Cohort StudyThrombotic and Bleeding Events Central Hospital, Nancy, France 310
Testing effectiveness (Phase 2)Study completedNCT01533441What this trial is testingVitamin K2 Intervention in Patients With Vitamin K AntagonistsWho this might be right forThrombosis Danisco 50
Testing effectiveness (Phase 2)Study completedNCT02981472What this trial is testingThe Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationWho this might be right forThrombosis Bristol-Myers Squibb 192
Not applicableStudy completedNCT02687854What this trial is testingReal-world Comparative Effectiveness of Apixaban Versus Vitamin K AntagonistWho this might be right forAtrial Fibrillation Bayer 18,591
Not applicableStudy completedNCT02596230What this trial is testingRE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous ThromboembolismWho this might be right forVenous Thromboembolism Boehringer Ingelheim 7,797